Pfizer Inc. (NYSE:PFE)‘s stock had its “outperform” rating restated by analysts at BMO Capital Markets in a research report issued on Tuesday. They presently have a $40.00 price target on the biopharmaceutical company’s stock. BMO Capital Markets’ target price indicates a potential upside of 22.36% from the company’s current price.

Several other brokerages have also issued reports on PFE. Sanford C. Bernstein set a $38.00 price target on Pfizer and gave the company a “buy” rating in a report on Tuesday, August 2nd. Barclays PLC restated an “equal weight” rating and issued a $34.00 target price on shares of Pfizer in a report on Tuesday, August 2nd. Vetr lowered Pfizer from a “buy” rating to a “hold” rating and set a $37.97 target price for the company. in a report on Thursday, July 14th. Jefferies Group set a $40.00 target price on Pfizer and gave the stock a “buy” rating in a report on Monday, August 1st. Finally, Piper Jaffray Cos. set a $54.00 target price on Pfizer and gave the stock a “buy” rating in a report on Monday, July 25th. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $38.63.

Analyst Recommendations for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) traded up 0.58% during mid-day trading on Tuesday, hitting $32.69. 14,823,025 shares of the stock were exchanged. The company has a 50-day moving average price of $33.95 and a 200-day moving average price of $34.35. The company has a market cap of $198.29 billion, a P/E ratio of 28.98 and a beta of 0.86. Pfizer has a one year low of $28.25 and a one year high of $37.39.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.02. The business earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The firm’s revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.56 EPS. On average, analysts predict that Pfizer will post $2.46 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be paid a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a dividend yield of 3.67%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 95.24%.

Several institutional investors have recently modified their holdings of PFE. Carlton Hofferkamp & Jenks Wealth Management LLC raised its position in shares of Pfizer by 4.6% in the third quarter. Carlton Hofferkamp & Jenks Wealth Management LLC now owns 63,318 shares of the biopharmaceutical company’s stock valued at $2,144,000 after buying an additional 2,769 shares during the period. GW&K Investment Management LLC raised its position in shares of Pfizer by 5.0% in the third quarter. GW&K Investment Management LLC now owns 1,055,259 shares of the biopharmaceutical company’s stock valued at $35,742,000 after buying an additional 50,416 shares during the period. Smith Chas P & Associates PA Cpas raised its position in shares of Pfizer by 2.1% in the third quarter. Smith Chas P & Associates PA Cpas now owns 585,441 shares of the biopharmaceutical company’s stock valued at $19,630,000 after buying an additional 11,796 shares during the period. Regent Investment Management LLC raised its position in shares of Pfizer by 8.9% in the third quarter. Regent Investment Management LLC now owns 46,262 shares of the biopharmaceutical company’s stock valued at $1,567,000 after buying an additional 3,770 shares during the period. Finally, Northside Capital Management LLC raised its position in shares of Pfizer by 8.6% in the third quarter. Northside Capital Management LLC now owns 12,260 shares of the biopharmaceutical company’s stock valued at $415,000 after buying an additional 970 shares during the period. 69.66% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

5 Day Chart for NYSE:PFE

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.